The Business of Hope
January 28, 2022But how reliable are the new drugs?
Pharmaceutical cancer research is in full swing. New products are constantly entering the market, promising patients longer and more pain-free lives. Others even hold out the prospect of a cure. Many of these treatments come to the market via an accelerated process. Often, they are accompanied by talk of major breakthroughs and new strategies: Targeted hormone therapy, antibody therapy, gene therapy.
Spending on cancer drugs has risen by more than 50 percent in recent years - to more than 8.6 billion Euros in 2019. It’s a profitable market for the pharmaceutical industry. But survival rates are not increasing as much as hoped.
"We are in a situation where we have more and more fast-tracked drugs with less and less certainty about the actual benefit. And we're in a situation where we're spending a lot of money on them," says Prof. Wolf-Dieter Ludwig, Chairman of the German Medical Association’s Drug Commission.
So, what is really known about the new cancer drugs? Their side-effects, benefits and potential harm they may cause? How well-researched are they before they come to market? Who controls their usage in practice? This documentary looks for answers.
Sendezeiten:
DW English
THU 03.02.2022 – 01:15 UTC
THU 03.02.2022 – 04:15 UTC
THU 03.02.2022 – 18:15 UTC
FRI 04.02.2022 – 09:15 UTC
SAT 05.02.2022 – 19:15 UTC
SUN 06.02.2022 – 02:15 UTC
Cape Town UTC +2 | Delhi UTC +5,5 | Hong Kong UTC +8
Lagos UTC +1 | Cape Town UTC +2 | Nairobi UTC +3
San Francisco UTC -8 | Edmonton UTC -7 | New York UTC -5
London UTC +0 | Berlin UTC +1 | Moscow UTC +3
DW Deutsch+
FRI 04.02.2022 – 09:15 UTC
Vancouver UTC -8 | New York UTC -5 | Sao Paulo UTC -3